These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9018394)

  • 1. Consideration of the relevance of ethological animal models for human repetitive behavioral spectrum disorders.
    Nurnberg HG; Keith SJ; Paxton DM
    Biol Psychiatry; 1997 Jan; 41(2):226-9. PubMed ID: 9018394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
    Korff S; Harvey BH
    Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: an ethological approach to the form of compulsive rituals.
    Eilam D; Szechtman H
    CNS Spectr; 2005 Mar; 10(3):191-202. PubMed ID: 15744221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.
    Denys D; Zohar J; Westenberg HG
    J Clin Psychiatry; 2004; 65 Suppl 14():11-7. PubMed ID: 15554783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder.
    Korff S; Stein DJ; Harvey BH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):348-55. PubMed ID: 17888556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin dysfunction disorders: a behavioral neurochemistry perspective.
    Petty F; Davis LL; Kabel D; Kramer GL
    J Clin Psychiatry; 1996; 57 Suppl 8():11-6. PubMed ID: 8698675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data.
    Lê AD; Tomkins DM; Sellers EM
    Alcohol Alcohol; 1996 Mar; 31 Suppl 1():27-32. PubMed ID: 8736998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
    Amiaz R; Fostick L; Gershon A; Zohar J
    Eur Neuropsychopharmacol; 2008 Jun; 18(6):455-61. PubMed ID: 18353618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder.
    Hedlund PB; Sutcliffe JG
    Neurosci Lett; 2007 Mar; 414(3):247-51. PubMed ID: 17267119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.
    Rojas-Corrales MO; Gibert-Rahola J; Mico JA
    Psychopharmacology (Berl); 2007 Feb; 190(2):221-31. PubMed ID: 17102981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
    Goddard AW; Shekhar A; Whiteman AF; McDougle CJ
    Drug Discov Today; 2008 Apr; 13(7-8):325-32. PubMed ID: 18405845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.